Assessing social and economic impact of subcutaneous mAbs in oncology:

Global & Regional Health Technology Assessment

AmericoCicchetti¹ 

关键词: Antibodies;    Monoclonal;    Health Technology Assessment;    Regression analysis;    Economic;    Social impact;    Patient Satisfaction;   

DOI  :  10.1177/2284240318757871

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

Background:Rituximab and trastuzumab were the first monoclonal antibodies (mAbs) approved for the treatment of cancer patients. Both antibodies are administered intravenously (EV), but subcutaneous (SC) formulations have recently been developed. SC formulations proved to be as safe and effective as EV and to offer substantial benefits to the patient.Objective:The aim of this study was to provide a multidimensional assessment of the impact of rituximab and trastuzumab SC compared to the EV formulation, providing a particular focus on expected social and economic benefits for the patient.Methods:The best established HTA methods were applied to gather and organize evidence concerning the clinical, economic, organizational, social and ethical impact of SC formulations of rituximab and trastuzumab. Social aspects were investigated applying regression methods to data collected with a previous research, while the potential savings associated with the use of SC formulations were estimated by a simple economic mod...

【 授权许可】

CC BY